title: [The analysis of failures in the treatment of children with chronic myelocytic leukemia in the studies of Polish pediatric leukemia/ lymphoma group].
abstract: 94 children with chronic myelocytic leukaemia--CML treated in period 1975-1998 were included in the study. Twenty seven of 60 children were treated with hydroxyurea or busulfan with 6 MP. In 33 children aged 1, 5-17 years IFN (Interferon alfa) was applied at the dose of 3 millions units every second day subcutaneously. Our data showed that IFN alfa could be applied as an alternative treatment in children with CML, who have not a donor for allogenic BMT (bone marrow transplantation).
authors.affiliation: Kliniki Hematologii i Chorób Rozrostowych Dzieci, Akademii Medycznej we Wrocławiu.
authors.forename: A
authors.initials: A
authors.lastname: Chybicka
authors.forename: J
authors.initials: J
authors.lastname: Bogusławska-Jaworska
authors.forename: K
authors.initials: K
authors.lastname: Kałwak
authors.forename: D
authors.initials: D
authors.lastname: Turkiewicz
authors.forename: J
authors.initials: J
authors.lastname: Armata
authors.forename: A
authors.initials: A
authors.lastname: Balcerska
authors.forename: M
authors.initials: M
authors.lastname: Cwiklińska
authors.forename: A
authors.initials: A
authors.lastname: Hicke-Roberts
authors.forename: M
authors.initials: M
authors.lastname: Kaczmarek-Kanold
authors.forename: P
authors.initials: P
authors.lastname: Kołecki
authors.forename: J
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: A
authors.initials: A
authors.lastname: Krauze
authors.forename: M
authors.initials: M
authors.lastname: Matysiak
authors.forename: A
authors.initials: A
authors.lastname: Płoszyńska
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: D
authors.initials: D
authors.lastname: Sońta-Jakimczyk
authors.forename: B
authors.initials: B
authors.lastname: Sikorska-Fic
authors.forename: H
authors.initials: H
authors.lastname: Wiśniewska-Slusarz
authors.forename: M
authors.initials: M
authors.lastname: Wysocki
authors.forename: J
authors.initials: J
authors.lastname: Wachowiak
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007223:Infant; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D011044:Poland; D012189:Retrospective Studies; D015996:Survival Rate; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D002066:Busulfan; D006918:Hydroxyurea